Ipilimumab/nivolumab/topotecanLack of efficacy and reactivation of tuberculosis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1852卷 / 1期

关键词：

D O I：

10.1007/s40278-021-94702-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：249 / 249

相关论文

共 50 条

[1] Ipilimumab/nivolumab/pembrolizumabLack of efficacy: case report
Reactions Weekly, 2024, 2030 (1) : 242 - 242
[2] Ipilimumab/nivolumab/pazopanibLack of efficacy: case report
Reactions Weekly, 2024, 2026 (1) : 163 - 163
[3] Ipilimumab/nivolumab/pembrolizumabLack of efficacy: case report
Reactions Weekly, 2022, 1907 (1) : 270 - 270
[4] Ipilimumab/nivolumab/pembrolizumabLack of efficacy: case report
Reactions Weekly, 2025, 2041 (1) : 200 - 200
[5] TopotecanLack of efficacy: case report
Reactions Weekly, 2022, 1920 (1) : 436 - 436
[6] Ipilimumab/Nivolumab/RelatlimabHypophysitis and lack of efficacy: case report
Reactions Weekly, 2024, 2038 (1) : 169 - 169
[7] Ipilimumab/nivolumab/MethylprednisoloneMyocarditis and lack of efficacy: case report
Reactions Weekly, 2025, 2052 (1) : 228 - 228
[8] Ipilimumab/nivolumab/pembrolizumabLack of efficacy and pain: case report
Reactions Weekly, 2023, 1943 (1) : 371 - 371
[9] Melphalan/topotecanLack of efficacy: case report
Reactions Weekly, 2022, 1928 (1) : 229 - 229
[10] Etoposide/topotecanLack of efficacy: case report
Reactions Weekly, 2023, 1947 (1) : 181 - 181

← 1 2 3 4 5 →